Mackenzie Financial
MRVI icon

Mackenzie Financial’s Maravai LifeSciences MRVI Stock Holding History

Mackenzie Financial’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.8M Buy
6,306,425
+132,769
+2% +$450K 0.02% 427
2025
Q4 		$20.1M Buy
6,173,656
+104,355
+2% +$351K 0.02% 384
2025
Q3 		$17.4M Hold
6,069,301
– – 0.02% 404
2025
Q2 		$14.6M Sell
6,069,301
-44,321
-0.7% -$93.2K 0.02% 418
2025
Q1 		$13.5M Sell
6,113,622
-69,094
-1% -$273K 0.02% 412
2024
Q4 		$33.7M Sell
6,182,716
-180,696
-3% -$1.16M 0.05% 265
2024
Q3 		$52.9M Buy
6,363,412
+502,771
+9% +$4.35M 0.07% 218
2024
Q2 		$42M Buy
5,860,641
+844,325
+17% +$7.29M 0.06% 236
2024
Q1 		$43.5M Sell
5,016,316
-152,860
-3% -$1.03M 0.06% 235
2023
Q4 		$33.9M Buy
5,169,176
+238,335
+5% +$1.54M 0.05% 258
2023
Q3 		$48.7M Buy
4,930,841
+1,384,455
+39% +$15.2M 0.08% 195
2023
Q2 		$44.1M Buy
3,546,386
+1,008,824
+40% +$13.6M 0.07% 228
2023
Q1 		$35.6M Buy
2,537,562
+416,401
+20% +$5.98M 0.05% 260
2022
Q4 		$30.4M Buy
2,121,161
+2,070,193
+4,062% +$32.6M 0.05% 268
2022
Q3 		$1.3M Buy
+50,968
New +$1.28M ﹤0.01% 779

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Mackenzie Financial's MRVI Position: Q1 2026 in Review

Mackenzie Financial increased its Maravai LifeSciences (MRVI) stake by 2.2% in Q1 2026, buying an estimated $450K and bringing the position to 6,306,425 shares worth $17.8M. The position accounts for 0.02% of the portfolio, ranked #427.

Mackenzie Financial first reported a position in MRVI in Q3 2022 and has held it in 15 quarters since. The position peaked at $52.9M in Q3 2024. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Mackenzie Financial held 6,306,425 shares of Maravai LifeSciences worth $17.8M as of Q1 2026.
  • Mackenzie Financial bought 132,769 Maravai LifeSciences shares in Q1 2026, an estimated $450K.
  • Maravai LifeSciences made up 0.02% of Mackenzie Financial's portfolio in Q1 2026, its #427 holding.
  • Mackenzie Financial first reported a position in Maravai LifeSciences in Q3 2022 and has held it in 15 quarters since.
  • Mackenzie Financial's Maravai LifeSciences position peaked at $52.9M in Q3 2024.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.